Life Sciences Archive » September, 2009

Life Sciences - September, 2009

192 articles

• Medmarc Ordered To Cover St. Jude Settlements
• Auxilium Wins Bid To Toss Most Of FLSA, Bias Suit
• Forest Settles Suit Over Celexa, Lexapro Kickbacks
• DC Circ. Backs Military's Mandated Anthrax Vaccine
• Taro Sues Sun Over Withholding Troubles At Unit
• Jury Finds Ex-Intermune CEO Guilty Of Wire Fraud
• ACCC Clears $68B Pfizer, Wyeth Deal With Conditions
• Govs. Call For Strong Biologic Data Protection
• Boston Scientific To Pay Cordis $716M In Stent War
• Elan Subpoenaed By SEC Over Drug Disclosures
• Glaxo Yanks Cervarix Batch After UK Death
• Lilly To Pay Conn. $25M Over Zyprexa Marketing
• Fen-Phen Plaintiffs Firm Hits Back In Insurance Spat
• NJ Supreme Court Upholds $4.5M Vioxx Verdict
• Kroes Vows More EC Antitrust Reviews For Drug Cos.
• Elan Files $600M Notes Offering, $850M Tender Offer
• Albion Drops Supplement Patent Suit Against Seton
• Insurer Fends Off Genzyme's Bid For Coverage
• China's Impending Disclosure Of Origin Law
• 1st Circ. Revives Consumer AWP Claims Against J&J
• Sandoz Admits To Infringing Ortho Tri-Cyclen Patent
• Antitrust Suit Against Big Pharma, Distributors Tossed
• Direct Purchasers Want Market Docs In Wellbutrin MDL
• Neurontin Plaintiffs Make Bid For Class Certification
• Catheter Antitrust Claims Against CR Bard Nixed
• Win For Health Care Boss Affirmed In Insurance Spat
• CVS, Wal-Mart Seek Toss Of Drug Overcharge Action
• Abbott To Buy Solvay's Pharma Unit For $6.6B Cash
• Albion Sues TriGen Over Iron Supplement Patent
• Eisai Urges Court To Toss Apotex Suit Over Aricept
• ReNu Economic Loss Plaintiffs Lose Bid For 2 Classes
• Genesis Biosystems Sues Over Liposuction Patent
• FDA Vet Joins Nixon Peabody From Latham & Watkins
• Covidien Snags Brain Monitor Co. Aspect For $210M
• Australian Towns Get OK To Pursue Lehman Claims
• Cordis Appeals $22M Verdict In Stent Patent Suit
• Janssen Alzheimer's Patent Not Valid: Fed. Circ.
• Sanofi Wins Dismissal Of Securities Action
• FDA Admits Knee Device Approval Was Compromised
• Deal Pros Brace For More Antitrust 2nd Looks
• Merck Diabetes Drugs Include Pancreatitis Risk: FDA
• Novartis, 2 Generics Drop Lotrel Patent Lawsuits
• Fed. Circ. Upholds AstraZeneca's Seroquel Patent Win
• Judge Favors Bayer In Livestock Drug Patent Spat
• Patent Reform And The Future Of Pharma Patents
• Stock Promoter Dropped From CellCyte Fraud Suit
• Guidance Loses Bid To Alter Damages Before Trial
• Cordis Wins 2nd Dismissal Of Stent Patent Suit
• Abbott Pays $27M To End C&D Pregnancy Test Feud
• MDL Judges Can't Meddle In Past Orders: 3rd Circ.
• Patient Groups Urge Congress To Support Biosimilars
• Senate Panel Plans Looser Rules On Pay-For-Delay
• Ex-McDermott, Dorsey Attys Face Insider Trading Trial
• Judge Quashes Teva Bid To Introduce Generic Evista
• FDA Taps IOM To Study Premarket Approval Process
• Wyeth Loses Bid For TRO On Generic Zosyn
• Supporting Patentability With Commercial Success
• AstraZeneca Loses $12.9M AWP Appeal
• Bristol-Myers Settles Wholesale Drug Price Suit
• Wyeth Sues FDA To Block Generic Zosyn
• Gilbert Lures Insurance Lawyer Back From Dickstein
• Pimco: Another Guidepost For Class Certification
• Mannatech, Rival Settle Supplement Patent Spat
• Wyeth, Cordis Sue Abbott, Boston Sci Over Stent
• Baucus Tweaks Bill To Make Health Care Cheaper
• Fed. Circ. Says Aneurysm Patents Weren't Infringed
• Wholesalers Drop Merck Antitrust Suit Over Singulair
• Insider Trading Rap Sticks To NBTY Lawyer
• Merck, Schering Win Initial OK For $42M Vytorin Deal
• AstraZeneca Seeks Ruling in Crestor Patent MDL
• Life Tech Sues Biosearch Tech Over Assay Patents
• Guidant Found Not Liable In Shocking Pacemaker Suit
• AstraZeneca Units Dropped From Pain Pump Suits
• PPA MDL Plaintiffs' Lawyers Divvy Up $15.5M
• Buyers Bullish On Future Of M&A: Survey
• Biogen Idec Launches $356M Tender Offer For Facet
• TriCor Purchasers Seek To Finalize $65M Settlement
• Teva Appeals Singulair Patent Suit To Fed. Circ.
• Sepracor Investor Sues Over Dainippon Takeover
• Acacia, AGFA Drop Imaging Patent Suit
• Pfizer Accuses Expert Of Tainting Doctor Testimony
• Levaquin MDL Continues To Grow
• Apotex Appeals Redaction Ruling In Wyeth Patent Suit
• Conrad O'Brien Snags Ex-Synthes Patent Chief
• Former Pfizer Counsel Joins Nixon Peabody
• Philadelphia At Center Of State Yaz Litigation
• Antitrust Claims Shorn In Eyelash Product Patent Suit
• Brown Rudnick Bags Cooley Patent Team
• FDA Says Allergan Misleads Public On Eyelash Drug
• J&J Closes $885M Alzheimer's Drug Deal With Elan
• Ex-Lehman Broker Gets Probation In Insider Case
• Ariz., Bristol-Myers Squibb Settle AWP Drug Case
• IPO Market Buzz Prompts Preparation For Better Days
• Tafas V. Doll: Repercussions Of En Banc
• FDA Warns Bayer About Testing At German Plant
• Bayer Asks Court To Scrap MDL On Aspirin Marketing
• DLA Piper Adds Patterson Belknap Chemist, Attorney
• Fed. Circ. Tosses Ruling For Mayo Nixing Test Patents
• Investor Class Action Strikes At CardioNet's Heart
• Monsanto Retirees Want Class OK'd In ERISA Fight
• FDA Insists On Box Warning For Promethazine
• Huntsman, Economy Hasten Push For Closing Clarity
• Reps Join Push To Reopen CVS Caremark Probe
• Micron Seeks To Trim Claims In Drug Contract Spat
• Sandoz, Dr. Reddy's Sued Over Allegra Patent
• BU Must Hand Over Docs In Paxil Birth Defect Case
• Biovail Unit Enters Guilty Plea In Kickbacks Case
• Fed. Circ. Keeps Ban On Roche's US Mircera Sales
• Schering-Plough, Merck Seek To Toss Vytorin Suit
• Feds Fight To Keep Protonix Bundling Suit Alive
• Plaintiff Seeks FDA Info In Apotex Preemption Case
• Teva Agrees To License Shire Patent For Carbatrol
• Arguing Preemption In The 11th Circ. Post-Levine
• Elan Says It Has Cured Tysabri Contract Breach
• Warner Chilcott Sues Lupin Over Femcon, Loestrin IP
• Court Braces For More GSK, P&G Denture Cream Suits
• 9th Circ. Backs Ban On Tobacco Sales In SF Pharmas
• Jury Lets Nova Off Hook In Trade Secrets Spat
• Medtronic Catheter, Tube Combo Prompts Recall
• Interference Claim Nixed In Guidance Antitrust Suit
• Upsher-Smith, Others Exit Namenda Patent Case
• Deal Contract Language Revamped After Meltdown
• Teva's Suit Over Aricept Infringement Tossed
• Fosamax Judge Calls A Mistrial In Bellwether Case
• Smiths Medical Recalls Tracheal Tubes
• Ex-Howrey IP Partner Joins Dechert
• CA On Verge Of Finalizing Web Browser Patent Win
• Derivative Suit Filed In Wake Of Record Pfizer Payout
• Fund Relaunches Trasylol Class Action Against Bayer
• Abbott Tries To Nix Amended HIV Drug Price Suits
• Medtronic Warns About Faulty Defibrillator Batteries
• Barroway Topaz Opens San Francisco Office
• Guidant Cleared In Death Of Toddler With Pacemaker
• Key Wins For Baxter Nixed In Dialysis Patent Suit
• Fed. Circ. Hands Sanofi Victory In Eloxatin Spat
• Abbott Snaps Up Evalve In $410M Deal
• Dentsply, Tulsa Fail To Nix Some Claims In Suit
• Lupin, Novartis Drop Patent Dispute Over Lotrel
• Jury Says Axiom Infringed Electrotherapy Patent
• Arthrex Wins Judgment In ACL Surgery Patent Suit
• Fosamax Jurors Get Daylong 'Cooling-Off Period'
• 'Viagra Missile' Shot Down For Violating Pfizer's IP
• Merck Loses Bid To Toss 24 Fosamax Cases
• Protests Over $2.6B Sepracor Deal Begin To Roll In
• Baxter Escapes Wrongful Death Suit In Heparin MDL
• TriCor Indirect Purchasers' Attys Seek $22M In Fees
• SEC Says CellCyte Swindled Stem Cell Investors
• Medline Seeks Injunction In 3M Hand Scrub Battle
• Burns & Levinson Snaps Up K&L Gates IP Experts
• FDA Pulls Unauthorized OTC Anti-Microbial Products
• AstraZeneca Aims To Cut NY, NJ Plaintiffs From MDL
• SC Says Lilly, Doctors Made Golf Bets Over Zyprexa
• Millennium, J&J Unit Take US Side In Velcade IP Suit
• Sanctions Sought In Discovery Spat V. Mutual Pharma
• Cadence Taps Latham For $100M Offering
• EPA Seeks OK For Alcatel, Pfizer Cleanup Cost Deal
• Dental Supply Cos. Seek Sanctions In Contract Spat
• Elan-J&J Deal Breaches Biogen Tysabri Deal: Court
• Pittsburgh Univ. Scientist Accused Of Cancer Fraud
• US Asks CIT To Dismiss Thermal Cycler Duties Action
• Fed Circ. Says Lonza Infringed Martek Patents
• Novartis Execs Best Derivative Shareholder Claims
• 1st Circ. Nixes Pharmacies' Appeal Of AWP Deals
• Purdue Appeals Par's Defeat Of Ultram Patents
• 6th Circ. Sides With Novartis In Retaliatory Firing Case
• Ex-Tyco Affiliate Covidien Inks Deals To Sell 2 Units
• Miss. Wants Teva Fraud Suit Back In State Court
• Dainippon To Acquire Sepracor For $2.6B
• Minn. High Court OKs Prempro Cases Against Wyeth
• Pharmacies Appeal AWP Class Action Settlement
• Thermo Fisher Scientific Snags Brahms For $470M
• Endo Looks To Join Genzyme-Impax Renagel Battle
• Skadden Health Group Nabs King & Spalding Partner
• Amgen, Roche OK Temporary Mircera Import Ban
• ICU Seeks Details On RyMed Expert In IV Valve Spat
• 2nd Circ. Deep-Sixes ERISA Lawsuit Against J&J
• Navinta Appeals Infringement Ruling Over Naropin
• LEO Pharma To Purchase Peplin For $287.5M
• Bronx Manager Hits Rite Aid With OT Class Action
• FDA Approves KV's Drug Manufacturing Plan
• Vioxx Litigation Group Keeps Up Protest Over Fee Cap
• Vytorin Securities Suits Survive Dismissal Bids
• Pfizer Finalizes $2.3B Bextra Off-Label Marketing Deal
• Schering-Plough ERISA Suit Tossed
• AMA Calls Myriad's Gene Patents Unconstitutional
• Abrika Looks To Protect Documents In Wellbutrin Case
• Apotex Slapped With Injunction In Fortical Patent Suit
• Ven-A-Care, Abbott Face Off In Drug Prices Suit
• Judge Slams Complaint Over Walgreens Drug Rate
• Cephalon Tries To Quash FTC Pay-For-Delay Suit
• Merck, Patient Seek Separate JMOL In Fosamax Trial
• No $473M Tax Refund For Schering-Plough: Judge